Back to portfolio
Inversago Pharma (www.inversago.com) focuses on the development of next-generation, peripherally-restricted endocannabinoid-1 (CB1) inverse agonists to treat type-1 diabetes, Prader-Willi syndrome and various metabolic diseases, such as non-alcoholic steatohepatitis (NASH) and obesity. Emerging from Dr George Kunos’ lab at the US National Institute of Health (NIH), lead candidates are currently tested preclinically.
